SCHEMBL18890757

SCHEMBL18890757

CCC(C)CN(C)Cc1ccccc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CARM1 Q86X55 1/20 0.48
PRMT6 Q96LA8 1/20 0.48
PRMT8 Q9NR22 1/20 0.48
TSHR P16473 4/20 0.48
ALDH1A1 P00352 3/20 0.48
LMNA P02545 2/20 0.47
ADRA2B P18089 1/20 0.47
ADRA2C P18825 1/20 0.47
SLC6A2 P23975 1/20 0.47
HTR2A P28223 1/20 0.47
SLC6A4 P31645 1/20 0.47
ADRA1A P35348 1/20 0.47
OPRK1 P41145 1/20 0.47
SLC6A3 Q01959 1/20 0.47
KCNH2 Q12809 1/20 0.47
USP2 O75604 1/20 0.47
CYP3A4 P08684 1/20 0.47
MAOA P21397 1/20 0.47
MAOB P27338 1/20 0.47
PYCR1 P32322 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19779234 0.85 CARM1 (0.46) CARM1PRMT6PRMT8TSHRALDH1A1
SCHEMBL17299909 0.82 SIGMAR1 (0.44) CARM1PRMT6PRMT8TSHRALDH1A1
SCHEMBL172668 0.82 TSHR (0.54) CARM1PRMT6PRMT8TSHRALDH1A1
SCHEMBL24969033 0.81 KDM4E (0.40) TSHRLMNAUSP2CYP3A4PYCR1
SCHEMBL10151711 0.81 CARM1 (0.55) CARM1PRMT6PRMT8TSHRALDH1A1
SCHEMBL14452299 0.80 TRPA1 (0.46) CARM1PRMT6PRMT8TSHRALDH1A1
SCHEMBL14923120 0.79 DNM1 (0.59) CARM1PRMT6PRMT8TSHRALDH1A1
SCHEMBL21910026 0.79 CARM1 (0.52) CARM1PRMT6PRMT8TSHRALDH1A1
SCHEMBL19715516 0.79 ALDH1A1 (0.47) CARM1PRMT6PRMT8TSHRALDH1A1
SCHEMBL13428461 0.79 CARM1 (0.52) CARM1PRMT6PRMT8TSHRALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10370388-B2 Heterocyclic compounds and methods of their use NOVARTIS AG (CH) 2019-08-06 US disclosed
WO-2017156194-A1 COMPOSITIONS AND METHODS FOR INHIBITING INFLUENZA RNA POLYMERASE PA ENDONUCLEASE THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2017-09-14 WO disclosed
US-20170145032-A1 HETEROCYCLIC COMPOUNDS AND METHODS OF THEIR USE SPINIFEX PHARMACEUTICALS PTY LTD (AU) 2017-05-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10370388-B2 Heterocyclic compounds and methods of their use AGTR2, AGTR1, BDKRB2 CARM1 4702/4885PRMT6 3233/4885PRMT8 3212/4885
US-20170145032-A1 HETEROCYCLIC COMPOUNDS AND METHODS OF THEIR USE AGTR2, AGTR1, BDKRB2 CARM1 4706/4885PRMT6 3238/4885PRMT8 3155/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.